Welcome to our dedicated page for Tenax Therapeutics news (Ticker: TENX), a resource for investors and traders seeking the latest updates and insights on Tenax Therapeutics stock.
Tenax Therapeutics Inc (TENX) is a clinical-stage pharmaceutical company developing therapies for cardiovascular and pulmonary diseases with high unmet needs. This page provides official updates on clinical trials, regulatory milestones, and corporate developments.
Investors and researchers will find a centralized repository of press releases and verified news related to Tenax's lead candidate levosimendan, including progress on the Phase 3 LEVEL study for PH-HFpEF. Track updates on intellectual property expansions, partnership announcements, and scientific presentations.
All content is curated to meet investor needs for timely, accurate information on drug development progress. Bookmark this page for direct access to primary source materials from Tenax Therapeutics, without promotional commentary or speculative analysis.
Tenax Therapeutics (NASDAQ: TENX) reported that a prespecified blinded sample size re-estimation (BSSR) for the Phase 3 LEVEL trial showed the study is powered at >90% to detect a 25-meter change in 6-minute walk distance (6MWD), with observed standard deviation in the first 150 randomized patients below the assumed 55 meters. Tenax confirmed no increase in target enrollment and reiterated that LEVEL enrollment is expected to complete in the first half of 2026, with topline data expected in the second half of 2026.
The company also initiated LEVEL-2, a global Phase 3 trial planning ~540 patients randomized 2:1 (TNX-103 vs placebo) with primary endpoint 6MWD at Week 26, selecting >100 sites across 15 countries and estimating enrollment completion by end of 2027. Tenax will open a global open-label extension to provide continued access to TNX-103.
Tenax Therapeutics (NASDAQ: TENX) will present at two investor conferences in early December 2025: a fireside chat at the 8th Annual Evercore Healthcare Conference on December 2, 2025 at 4:15 p.m. ET, and a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 4, 2025 at 11:30 a.m. ET.
Participants include Chris Giordano, President & CEO, and Stuart Rich, M.D., Chief Medical Officer. Live and archived webcasts will be available from the company’s investor relations webpage.
Tenax Therapeutics (NASDAQ: TENX) reported Q3 2025 results and clinical updates on Nov 12, 2025. The company expects to enroll 230 patients in the Phase 3 LEVEL study in H1 2026 with topline data H2 2026, and remains on track to initiate the global LEVEL-2 registrational study in 2025 with >160 qualified sites across 15 countries. The European Patent Office issued an Intent to Grant a patent covering levosimendan for PH-HFpEF, with a term to Dec 2040 and possible SPC extension. Cash and equivalents were $99.4M at Sept 30, 2025, with runway through 2027. Q3 operating costs rose and net loss widened to $15.8M.
The company will host a virtual KOL call on Nov 13, 2025 at 4:30 p.m. ET.
Tenax Therapeutics (NASDAQ: TENX) will host a virtual KOL call on November 13, 2025 at 4:30 p.m. ET to discuss the PH-HFpEF treatment landscape and the late-stage program for TNX-103 (oral levosimendan).
Panelists include Tenax management and KOLs Barry A. Borlaug, M.D., and Sanjiv J. Shah, M.D. The company is advancing TNX-103 in two registrational Phase 3 studies, LEVEL (North American enrollment ongoing) and LEVEL-2 (global study on track to initiate in 2025). The call will be available live and archived via the company investor relations webpage; dial-in numbers are provided for U.S. and international callers.
Tenax Therapeutics (NASDAQ: TENX) will present at the Guggenheim 2nd Annual Healthcare Innovation Conference in Boston from November 10-12, 2025. The company's presentation is a fireside chat on November 10, 2025 at 4:00 p.m. ET, featuring Chris Giordano, President & Chief Executive Officer, and Stuart Rich, M.D., Chief Medical Officer. A live webcast and archived replay will be available on the company's investor relations webpage.
Tenax Therapeutics (NASDAQ:TENX) announced that the European Patent Office (EPO) intends to grant a patent for the use of levosimendan, including TNX-103, in treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF). The patent will provide protection through December 2040, with potential for extension beyond.
The patent will cover multiple administration routes including oral, intravenous, inhaled, transdermal, and subcutaneous use, as well as levosimendan's active metabolites. This development comes as Tenax prepares to launch its LEVEL-2 Phase 3 study in Europe, expanding their global clinical trial presence.
Tenax Therapeutics (NASDAQ: TENX), a Phase 3 development-stage pharmaceutical company focused on cardiopulmonary therapies, will participate in the Cantor Global Healthcare Conference 2025. The company's presentation will take the format of a fireside chat featuring President & CEO Chris Giordano and Chief Medical Officer Dr. Stuart Rich.
The presentation is scheduled for September 4, 2025, at 10:20 a.m. ET in New York. Investors can access both the live and archived webcast through the company's investor relations webpage.
Tenax Therapeutics (NASDAQ:TENX) reported Q2 2025 financial results and provided updates on its Phase 3 clinical programs. The company's lead program, TNX-103 (oral levosimendan), is progressing in the Phase 3 LEVEL study for PH-HFpEF treatment, with enrollment completion of 230 patients expected in H1 2026.
Key financial metrics include cash position of $105.5 million as of June 30, 2025, expected to fund operations through 2027. Q2 2025 resulted in a net loss of $10.9 million, with R&D expenses of $6.1 million and G&A expenses of $5.7 million.
The company secured patent protection in Canada extending to 2040 and remains on track to initiate its second Phase 3 study, LEVEL-2, in 2025 with a global footprint across 15 additional countries.
Tenax Therapeutics (NASDAQ: TENX) reported its Q1 2025 financial results and provided updates on its Phase 3 clinical trials. The company expects to complete enrollment of 230 patients in its Phase 3 LEVEL study for TNX-103 in PH-HFpEF by year-end 2025, with topline data expected mid-2026. A second Phase 3 study, LEVEL-2, is planned to commence in 2025.
Financial highlights include: cash position of $111.4 million as of March 31, 2025, bolstered by a $25 million private placement in March 2025. Q1 2025 saw increased expenses with R&D costs at $5.7 million (up from $2.7M in Q1 2024) and G&A expenses at $5.7 million (up from $1.2M). Net loss widened to $10.4 million compared to $3.8M in Q1 2024. The company expects current cash to fund operations through 2027.
Tenax Therapeutics (NASDAQ: TENX), a Phase 3 development-stage pharmaceutical company focused on cardiopulmonary therapies, has announced its participation in the 24th Annual Needham Virtual Healthcare Conference.
The conference will be held virtually from April 7-10, 2025. The company's corporate presentation is scheduled for April 7, 2025, at 3:45 p.m. ET. Key participants include Chris Giordano (President & CEO), Dr. Stuart Rich (Chief Medical Officer), and Doug Randall (Chief Business Officer).
Both live and archived versions of the presentation will be available through the company's investor relations webpage.
FAQ
What is the current stock price of Tenax Therapeutics (TENX)?
What is the market cap of Tenax Therapeutics (TENX)?
